Identify early striatal metabolite changes
- Trial ID
- NCT04735172
- Official Title
- Exploration of Differences in Metabolite Concentrations by 7Teslas NMR Spectroscopy in Striatum and Subthalamic Nuclei in de Novo Parkinsonian Patients and Control Subjects
- Goal
- Identify early striatal metabolite changes
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- University Hospital, Clermont-Ferrand
- Study Type
- INTERVENTIONAL
- Enrollment
- 44 participants
- Conditions
- Parkinson's Disease
- Interventions
- specific MRI Acquisition (NMR spectroscopy) at 7T
Plain-Language Summary
The goal is to detect early biochemical changes in the striatum and subthalamic nucleus in people with Parkinson's, looking for differences in brain metabolites that could serve as biomarkers of disease. The approach uses ultra‑high field 7 Tesla NMR spectroscopy, a noninvasive MRI method that measures concentrations of chemicals like glutamate, GABA, and N‑acetylaspartate with very high resolution in small deep brain regions, without using contrast agents. They are enrolling adults 18 to 75 with early, untreated Parkinson's (Hoehn and Yahr stage I,II, disease duration up to 5 years), with preserved cognition (MoCA > 24), no severe tremor or MRI contraindications, no psychotropic medications or deep brain stimulation, and similar-age healthy controls.
Locations
- Chu Clermont Ferrand, Clermont-Ferrand, France
- CHU Poitiers, Poitiers, France
Frequently Asked Questions
- What is this trial testing?
- This trial is studying specific MRI Acquisition (NMR spectroscopy) at 7T. The goal is to detect early biochemical changes in the striatum and subthalamic nucleus in people with Parkinson's, looking for differences in brain metabolites that could serve as biomarkers of disease. The approach uses ultra‑high field 7 Tesla NMR spectroscopy, a noninvasive MRI method that measures concentrations of chemicals like glutamate, GABA, and N‑acetylaspartate with very high resolution in small deep brain regions, without using contrast agents. They are enrolling adults 18 to 75 with early, untreated Parkinson's (Hoehn and Yahr stage I,II, disease duration up to 5 years), with preserved cognition (MoCA > 24), no severe tremor or MRI contraindications, no psychotropic medications or deep brain stimulation, and similar-age healthy controls.
- Who can participate?
- Participants must be between 18 Years and 75 Years.
- Where is this trial located?
- This trial is recruiting at 2 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 7 years and 4 months.